-- 獨立研究機構CFRA向提供了以下研究報告。 CFRA分析師的觀點摘要如下: CE公司公佈2026年第一季每股收益為0.85美元,高於去年同期的0.54美元,較市場預期低0.05美元;營收為23.37億美元,季增6%,但年減2%,低於預期900萬美元。工程材料業務營運表現強勁,銷售額達13.25億美元(年增3%),營業利潤率提升至17%,營業利潤從9,400萬美元飆升至2.21億美元,反映了產品組合優化和成本削減措施的成功實施。管理層推進了一系列結構性舉措,包括關閉新加坡尼龍工廠以及加強在亞洲和歐洲的業務網絡。管理層將全年自由現金流預期上調至7億至8億美元,並給出第二季每股收益預期為2.00至2.40美元,預計下半年每股收益約為3.00美元。該公司計劃透過持續產生現金流,將淨債務/經營 EBITDA 比率改善至 4.8 倍,但第一季自由現金流僅為 300 萬美元,反映了季節性營運資金的時間安排,並凸顯了在高槓桿率的情況下降低債務的重要性。
Related Articles
Simcere Pharmaceutical Receives Chinese Regulatory Approval to Begin Trials of Tumor Drug
Simcere Pharmaceutical (HKG:2096) received Chinese regulatory approval to begin clinical trials of SIM0613, according to a Hong Kong bourse filing Wednesday.The injection is intended to treat advanced solid tumors and is licensed to Ipsen Pharma in regions outside Greater China.
Meitu Records 30% Rise in Paying Subscribers
Meitu (HKG:1357) said the number of paying subscribers using its platform grew 30% year on year to 17.90 million as of end March, according to a Hong Kong bourse filing Wednesday.Paying subscribers for the company's productivity tools grew 53% to 2.34 million, while leisure app subscribers increased 27% to 15.56 million, the firm said.The company's core revenue grew 34.3% year on year to 852 million yuan, while other businesses remained "stable overall."The company's annual recurring revenue for AI-driven productivity apps stood at 580 million yuan as of March, a 56% increase from a year earlier.
Yidu Tech Unit Wins SG$2.3 Million Singapore Healthcare Project
Yidu Tech (HKG:2158) said its subsidiary EVYD Research Private Limited won a contract from Singapore Health Services for the implementation and support of Dr Buddy, according to a Wednesday Hong Kong bourse filing.The total project amount is about SG$2.3 million.